[go: up one dir, main page]

LT2767546T - Lipoproteino kompleksai ir jų gamyba bei panaudojimai - Google Patents

Lipoproteino kompleksai ir jų gamyba bei panaudojimai

Info

Publication number
LT2767546T
LT2767546T LTEP14150349.0T LT14150349T LT2767546T LT 2767546 T LT2767546 T LT 2767546T LT 14150349 T LT14150349 T LT 14150349T LT 2767546 T LT2767546 T LT 2767546T
Authority
LT
Lithuania
Prior art keywords
manufacturing
lipoprotein complexes
uses therof
therof
lipoprotein
Prior art date
Application number
LTEP14150349.0T
Other languages
English (en)
Inventor
Jean-Louis Dasseux
Daniela Carmen Oniciu
Rose ACKERMANN
Original Assignee
Cerenis Therapeutics Holding Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerenis Therapeutics Holding Sa filed Critical Cerenis Therapeutics Holding Sa
Publication of LT2767546T publication Critical patent/LT2767546T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP14150349.0T 2011-02-07 2012-02-06 Lipoproteino kompleksai ir jų gamyba bei panaudojimai LT2767546T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161440371P 2011-02-07 2011-02-07
US201161452630P 2011-03-14 2011-03-14
US201161487263P 2011-05-17 2011-05-17

Publications (1)

Publication Number Publication Date
LT2767546T true LT2767546T (lt) 2019-02-25

Family

ID=45592833

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP12703947.7T LT2673296T (lt) 2011-02-07 2012-02-06 Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai
LTEP14150349.0T LT2767546T (lt) 2011-02-07 2012-02-06 Lipoproteino kompleksai ir jų gamyba bei panaudojimai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP12703947.7T LT2673296T (lt) 2011-02-07 2012-02-06 Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai

Country Status (28)

Country Link
US (8) US20120232005A1 (lt)
EP (4) EP4400511A3 (lt)
JP (5) JP6219170B2 (lt)
KR (1) KR20140053848A (lt)
CN (4) CN103443123B (lt)
AU (1) AU2012214672B2 (lt)
CA (1) CA2826158A1 (lt)
CY (2) CY1121317T1 (lt)
DK (3) DK3466969T3 (lt)
ES (3) ES2994009T3 (lt)
HK (1) HK1198834A1 (lt)
HR (2) HRP20190072T1 (lt)
HU (2) HUE042314T2 (lt)
IL (1) IL227634B (lt)
IN (1) IN2013DN07828A (lt)
LT (2) LT2673296T (lt)
MX (2) MX343907B (lt)
PH (2) PH12013501644A1 (lt)
PL (2) PL2673296T3 (lt)
PT (2) PT2767546T (lt)
RS (2) RS58275B1 (lt)
RU (2) RU2017126088A (lt)
SG (2) SG192693A1 (lt)
SI (2) SI2673296T1 (lt)
SM (2) SMT201900194T1 (lt)
TW (2) TW201240671A (lt)
WO (1) WO2012109162A1 (lt)
ZA (1) ZA201305628B (lt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
DK3178481T3 (en) 2010-06-30 2019-04-08 Csl Ltd FORMULATION WITH RECONSTITUTED HIGH DENSITY LIPOPROTEIN AND PROCEDURE FOR PREPARING THEREOF
JP6219170B2 (ja) 2011-02-07 2017-10-25 セレニス セラピューティクス ホールディング エスアー リポタンパク質複合体ならびにその製造および使用
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
JP2016509068A (ja) * 2013-02-28 2016-03-24 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ クロマチン欠損細胞培養採取物からの抗体のクロマトグラフィー精製
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
SG10201804887YA (en) 2013-03-15 2018-07-30 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
CA2920391C (en) * 2013-08-08 2023-03-28 Csl Limited Contaminant removal method
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
CN106488987A (zh) 2014-05-02 2017-03-08 塞勒尼斯医疗控股公司 Hdl疗法标志物
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
KR101671580B1 (ko) * 2014-08-26 2016-11-02 영남대학교 산학협력단 미녹시딜 수용액 제조방법
WO2016123365A1 (en) 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Liposomal particles comprising biological molecules and uses thereof
US11219673B2 (en) 2015-03-25 2022-01-11 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
US11642419B2 (en) 2015-03-25 2023-05-09 The Regents Of The University Of Michigan Compositions and methods for treating cardiovascular related disorders
CA3032229A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sa Therapeutic combinations to treat red blood cell disorders
WO2018029505A1 (en) 2016-08-11 2018-02-15 Cerenis Therapeutics Holding Sa Cer-001 therapy for treating familial primary hypoalphalipoproteinemia
WO2018136866A1 (en) * 2017-01-23 2018-07-26 Hdl Therapeutics, Inc. Methods for treating cholesterol-related diseases
ES2681124B1 (es) 2017-03-08 2019-06-19 Fund Imdea Alimentacion Usos medicos de la apolipoproteina a y de activadores de la misma
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
EP3668600B1 (en) * 2017-08-10 2024-05-15 Abionyx Pharma SA Cargomers
US12220462B1 (en) 2018-02-13 2025-02-11 Abionyx Pharma Sa Complexes for delivery of cyclic dinucleotides
MX2020013633A (es) * 2018-07-03 2021-03-25 Bristol Myers Squibb Co Metodos para producir proteinas recombinantes.
JP2020138941A (ja) * 2019-02-28 2020-09-03 国立研究開発法人理化学研究所 バイセル及びその利用
JP2023502496A (ja) 2019-11-20 2023-01-24 アルカヘスト，インコーポレイテッド 肝臓再生に使用するための血漿画分
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
US11969280B2 (en) 2020-01-07 2024-04-30 Cleerly, Inc. Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
IL297046A (en) 2020-04-16 2022-12-01 Abionyx Pharma Sa Treatment of kidney disease using cer-001
WO2021209808A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Cer-001 therapy for treating kidney disease
JP2023522889A (ja) 2020-04-16 2023-06-01 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法
US20240000948A1 (en) 2020-10-01 2024-01-04 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
US20240050522A1 (en) * 2020-12-11 2024-02-15 The Regents Of The University Of Michigan COMPOSITIONS AND METHODS FOR PREVENTING, ATTENUATING, AND TREATING MEDICAL CONDITIONS WITH sHDL NANOPARTICLES
WO2022150631A1 (en) * 2021-01-08 2022-07-14 Hdl Therapeutics, Inc Systems and methods for reducing low attenuation plaque and/or plaque burden in patients
KR20240018430A (ko) 2021-04-15 2024-02-13 아비오닉스 파마 에스에이 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용
AU2022275694A1 (en) * 2021-05-19 2023-11-16 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
US20230289963A1 (en) * 2022-03-10 2023-09-14 Cleerly, Inc. Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination
KR20240167701A (ko) 2022-04-06 2024-11-27 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 안질환을 치료하는 방법
EP4504233A1 (en) 2022-04-06 2025-02-12 Abionyx Pharma SA Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
IL317446A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating acute conditions using complexes based on lipid-binding proteins
KR20250035547A (ko) 2022-06-28 2025-03-12 아비오닉스 파마 에스에이 스핑고미엘린의 합성을 위한 화합물 및 공정
KR20240009061A (ko) * 2022-07-13 2024-01-22 (재)씨젠의료재단 혈청 내 다중 아포지단백질의 직접정량 방법
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
AU587989B2 (en) 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
EP0209543A4 (en) 1984-12-31 1989-07-11 Internat Genetic Engineering I FRAGMENTS OF HUMAN APOLIPOPROTEINS PEPTIDES, TYPE-SPECIFIC ANTIBODIES AND METHODS OF USE.
GB8625435D0 (en) 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
IT1229996B (it) 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
WO1993000443A1 (en) 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification of recombinant apolipoprotein e from bacteria
US5408038A (en) * 1991-10-09 1995-04-18 The Scripps Research Institute Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
AU5457294A (en) 1992-10-29 1994-05-24 Board Of Regents, The University Of Texas System Adenovirus-mediated ldl receptor gene transfer and targeting
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US5643757A (en) 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
WO1995025749A2 (en) 1994-03-22 1995-09-28 Research Corporation Technologies, Inc. Eating suppressant peptides
IL109558A (en) 1994-05-04 2004-08-31 Yissum Res Dev Co DNA structures Derived from the SV40 virus that include DNA sequences External
US5932536A (en) 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
GB9919713D0 (en) 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
AU784506B2 (en) 1999-08-25 2006-04-13 Immunex Corporation Compositions and methods for improved cell culture
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
US20030224415A1 (en) 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
KR100545945B1 (ko) 2000-07-03 2006-01-25 갈라 디자인, 인크. 발현 벡터
AU7161401A (en) 2000-07-03 2002-01-14 Gala Design Inc Host cells containing multiple integrating vectors
US6852510B2 (en) 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP1335938B1 (en) * 2000-11-10 2010-09-22 F. Hoffmann-La Roche Ltd. Apolipoprotein construct
CA2429473C (en) 2000-11-20 2011-02-15 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
EP1366062B1 (en) 2001-02-23 2011-07-27 Immunex Corporation Efficient recovery of correctly refolded proteins
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
CA2457840C (en) 2001-08-20 2011-10-11 Zlb Bioplasma Ag Hdl for the treatment of stroke and other ischemic conditions
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
AU2003239489A1 (en) * 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
BR0313069A (pt) * 2002-07-30 2007-07-17 Esperion Therapeutics Inc métodos de tratamento de um ser humano sofrendo de um distúrbio associado com dislipidemia e de tratamento de um paciente sofrendo de uma infecção, composição farmacêutica, complexo de lipìdeo-proteìna apoa-i animal não-humana, e, método de administração da composição
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
EP2368565B1 (en) * 2003-07-03 2015-06-24 HDL Therapeutics, Inc. Enrichment of pre-beta high density lipoproteins
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
BRPI0513402A (pt) * 2004-07-16 2008-05-06 Tufts College miméticos de apolipoproteìna a1 e usos dos mesmos
US20060030525A1 (en) 2004-07-23 2006-02-09 Xencor, Inc. Apolipoprotein A-I derivatives with altered immunogenicity
US8206750B2 (en) * 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
CN101253195A (zh) * 2005-08-26 2008-08-27 科莱尼斯医疗控股公司 用于在乳酸菌中制备载脂蛋白基因产物的组合物和方法
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
WO2008104890A2 (en) * 2007-02-28 2008-09-04 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein
WO2008141230A1 (en) * 2007-05-09 2008-11-20 Lawrence Livermore National Security, Llc Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
US8436152B2 (en) 2007-08-17 2013-05-07 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin andapolipoprotein A-1
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
CA2703962A1 (en) * 2007-10-23 2009-04-30 The Cleveland Clinic Foundation Oxidant resistant apolipoprotein a-1 and mimetic peptides
BRPI0915093A2 (pt) * 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugados para a administração de compostos biologicamente ativos
WO2010093918A1 (en) 2009-02-16 2010-08-19 Cerenis Therapeutics Sa Apolipoprotein a-i mimics
US10525152B2 (en) * 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
JP6219170B2 (ja) 2011-02-07 2017-10-25 セレニス セラピューティクス ホールディング エスアー リポタンパク質複合体ならびにその製造および使用
CA2830664A1 (en) * 2011-03-25 2012-10-04 The Trustees Of Columbia University In The City Of New York Pegylated human hdl particle and process for production thereof

Also Published As

Publication number Publication date
US10322163B2 (en) 2019-06-18
CN105288589A (zh) 2016-02-03
DK2673296T3 (en) 2019-02-18
CN107337728A (zh) 2017-11-10
JP6219170B2 (ja) 2017-10-25
EP3466969A1 (en) 2019-04-10
JP2022050603A (ja) 2022-03-30
SG10201801372YA (en) 2018-04-27
AU2012214672B2 (en) 2015-10-01
TW201240671A (en) 2012-10-16
PT2767546T (pt) 2019-01-28
EP2673296B1 (en) 2018-10-24
PH12016500191A1 (en) 2017-10-18
CY1121317T1 (el) 2020-05-29
MX2013009083A (es) 2014-02-03
US20220362336A1 (en) 2022-11-17
JP2018076286A (ja) 2018-05-17
JP6720126B2 (ja) 2020-07-08
EP2767546A1 (en) 2014-08-20
CY1121318T1 (el) 2020-05-29
RU2627173C2 (ru) 2017-08-03
RU2013139066A (ru) 2015-03-20
JP2020176122A (ja) 2020-10-29
US10328119B2 (en) 2019-06-25
EP4400511A3 (en) 2024-09-04
SG192693A1 (en) 2013-09-30
US20150152164A1 (en) 2015-06-04
JP2024170492A (ja) 2024-12-10
DK2767546T3 (en) 2019-02-04
JP7009559B2 (ja) 2022-01-25
SI2767546T1 (sl) 2019-03-29
KR20140053848A (ko) 2014-05-08
EP2673296A1 (en) 2013-12-18
JP2014506884A (ja) 2014-03-20
MX355159B (es) 2018-04-06
ES2716349T3 (es) 2019-06-12
ZA201305628B (en) 2014-04-30
CN105294859A (zh) 2016-02-03
DK3466969T3 (da) 2024-07-22
US20240000887A1 (en) 2024-01-04
SMT201900045T1 (it) 2019-02-28
CN103443123A (zh) 2013-12-11
SMT201900194T1 (it) 2019-05-10
EP2767546B1 (en) 2018-10-17
MX343907B (es) 2016-11-28
EP3466969B1 (en) 2024-05-08
PH12013501644A1 (en) 2013-10-14
US9187551B2 (en) 2015-11-17
IL227634B (en) 2020-05-31
AU2012214672A1 (en) 2013-05-02
US20160095901A1 (en) 2016-04-07
US11998587B2 (en) 2024-06-04
CA2826158A1 (en) 2012-08-16
PL2767546T3 (pl) 2019-04-30
EP4400511A2 (en) 2024-07-17
PT2673296T (pt) 2019-01-31
TW201737935A (zh) 2017-11-01
HK1198834A1 (en) 2015-06-12
ES2994009T3 (en) 2025-01-15
NZ613524A (en) 2015-10-30
IL227634A0 (en) 2013-09-30
RS58243B1 (sr) 2019-03-29
HRP20190072T1 (hr) 2019-03-08
US11376309B2 (en) 2022-07-05
HRP20190138T1 (hr) 2019-03-22
SI2673296T1 (sl) 2019-03-29
US20140213501A1 (en) 2014-07-31
RU2017126088A (ru) 2019-01-31
CN107337728B (zh) 2023-05-23
US20230372441A1 (en) 2023-11-23
PL2673296T3 (pl) 2019-03-29
US11969456B2 (en) 2024-04-30
CN103443123B (zh) 2020-05-29
WO2012109162A1 (en) 2012-08-16
RS58275B1 (sr) 2019-03-29
HUE041797T2 (hu) 2019-05-28
US20190298800A1 (en) 2019-10-03
HUE042314T2 (hu) 2019-06-28
IN2013DN07828A (lt) 2015-07-03
US20120232005A1 (en) 2012-09-13
LT2673296T (lt) 2019-02-25
ES2717455T3 (es) 2019-06-21

Similar Documents

Publication Publication Date Title
HRP20190072T1 (hr) Lipoproteinski kompleksi i njihova proizvodnja i uporaba
HRP20190135T1 (hr) 4-imidazopiridazin-1-yl-benzamidi i 4-imidazotriazin-1-yl-benzamidi kao inhibitori btk
IL233051A0 (en) Anti-phf-tau antibodies and uses thereof
TWI561618B (en) Polishing component
IL229844B (en) Anti-psgl-1 antibodies and their use
ZA201404485B (en) Peer-to-peer payment registration and activation
EP2716359A4 (en) COMPLEX AND USES THEREOF
GB201111775D0 (en) Compounds and uses thereof
EP2815141A4 (en) BEARING COMPONENT
PL2667710T3 (pl) Kompozycja owadobójcza i związane z nią sposoby
EP2728198A4 (en) TURBO
GB201104522D0 (en) Complexes
EP2733360A4 (en) TURBO
GB201100924D0 (en) Surfaces
GB201211820D0 (en) Blisk manufacturing
GB201121726D0 (en) Compounds and uses thereof
GB201121551D0 (en) Compounds and uses thereof
GB201116360D0 (en) Glycobiological surfaces
LT3689878T (lt) 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk inhibitoriai
AU340099S (en) Trousers